Cowen began coverage on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a research report issued on Monday, The Fly reports. The brokerage set an “outperform” rating and a $32.00 price target on the stock. Cowen’s price objective points to a potential upside of 54.59% from the company’s previous close.

MIST opened at $20.70 on Monday. Milestone Pharmaceuticals has a twelve month low of $15.09 and a twelve month high of $22.13.

In other Milestone Pharmaceuticals news, major shareholder Holdings A/S Novo purchased 333,333 shares of the stock in a transaction dated Monday, May 13th. The shares were bought at an average price of $15.00 per share, with a total value of $4,999,995.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Rtw Investments, Lp purchased 666,667 shares of the stock in a transaction dated Thursday, May 9th. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $10,000,005.00. The disclosure for this purchase can be found here.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.

Further Reading: Economic Reports

The Fly

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with's FREE daily email newsletter.